Mainz Biomed (MYNZ) Competitors $1.75 -0.01 (-0.57%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$1.80 +0.05 (+2.86%) As of 08/22/2025 06:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock MYNZ vs. BDRX, RNTX, NNVC, TENX, JATT, BTAI, FBLG, MIRA, NAII, and CVKDShould you be buying Mainz Biomed stock or one of its competitors? The main competitors of Mainz Biomed include Biodexa Pharmaceuticals (BDRX), Rein Therapeutics (RNTX), NanoViricides (NNVC), Tenax Therapeutics (TENX), JATT Acquisition (JATT), BioXcel Therapeutics (BTAI), FibroBiologics (FBLG), MIRA Pharmaceuticals (MIRA), Natural Alternatives International (NAII), and Cadrenal Therapeutics (CVKD). These companies are all part of the "pharmaceutical products" industry. Mainz Biomed vs. Its Competitors Biodexa Pharmaceuticals Rein Therapeutics NanoViricides Tenax Therapeutics JATT Acquisition BioXcel Therapeutics FibroBiologics MIRA Pharmaceuticals Natural Alternatives International Cadrenal Therapeutics Mainz Biomed (NASDAQ:MYNZ) and Biodexa Pharmaceuticals (NASDAQ:BDRX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, risk, earnings, media sentiment, valuation and institutional ownership. Which has more volatility and risk, MYNZ or BDRX? Mainz Biomed has a beta of 0.25, indicating that its share price is 75% less volatile than the S&P 500. Comparatively, Biodexa Pharmaceuticals has a beta of 0.98, indicating that its share price is 2% less volatile than the S&P 500. Which has preferable valuation and earnings, MYNZ or BDRX? Biodexa Pharmaceuticals has lower revenue, but higher earnings than Mainz Biomed. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMainz Biomed$890K9.01-$21.65M-$65.60-0.03Biodexa PharmaceuticalsN/AN/A-$7.32MN/AN/A Do insiders and institutionals hold more shares of MYNZ or BDRX? 17.5% of Biodexa Pharmaceuticals shares are held by institutional investors. 18.2% of Mainz Biomed shares are held by company insiders. Comparatively, 0.3% of Biodexa Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Is MYNZ or BDRX more profitable? Company Net Margins Return on Equity Return on Assets Mainz BiomedN/A N/A N/A Biodexa Pharmaceuticals N/A N/A N/A Do analysts prefer MYNZ or BDRX? Mainz Biomed currently has a consensus price target of $14.00, suggesting a potential upside of 700.00%. Given Mainz Biomed's stronger consensus rating and higher probable upside, equities analysts clearly believe Mainz Biomed is more favorable than Biodexa Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mainz Biomed 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50Biodexa Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media refer more to MYNZ or BDRX? In the previous week, Biodexa Pharmaceuticals had 3 more articles in the media than Mainz Biomed. MarketBeat recorded 3 mentions for Biodexa Pharmaceuticals and 0 mentions for Mainz Biomed. Mainz Biomed's average media sentiment score of 0.00 equaled Biodexa Pharmaceuticals'average media sentiment score. Company Overall Sentiment Mainz Biomed Neutral Biodexa Pharmaceuticals Neutral SummaryMainz Biomed beats Biodexa Pharmaceuticals on 5 of the 9 factors compared between the two stocks. Get Mainz Biomed News Delivered to You Automatically Sign up to receive the latest news and ratings for MYNZ and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MYNZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MYNZ vs. The Competition Export to ExcelMetricMainz BiomedMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.06M$3.11B$5.75B$9.62BDividend YieldN/A2.23%4.40%4.10%P/E Ratio-0.0321.2831.3026.05Price / Sales9.01345.81432.98193.75Price / CashN/A43.1937.7358.48Price / Book0.678.129.536.61Net Income-$21.65M-$54.72M$3.26B$265.65M7 Day Performance-1.13%2.62%2.13%2.02%1 Month Performance-15.87%2.68%2.80%-0.31%1 Year Performance-87.81%10.93%30.68%19.06% Mainz Biomed Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MYNZMainz Biomed1.9437 of 5 stars$1.75-0.6%$14.00+700.0%-87.4%$8.06M$890K-0.0330Short Interest ↑Gap UpBDRXBiodexa Pharmaceuticals0.3255 of 5 stars$6.89-3.4%N/AN/A$26.06M$470K0.0020Gap DownRNTXRein TherapeuticsN/A$1.16+4.5%N/AN/A$25.58MN/A0.009News CoverageAnalyst DowngradeNNVCNanoViricides0.7275 of 5 stars$1.54-2.5%N/A-21.7%$24.75MN/A-2.1420Gap UpTENXTenax Therapeutics1.6216 of 5 stars$5.85-1.0%$17.50+199.1%+39.2%$24.52MN/A-2.369JATTJATT AcquisitionN/A$1.42-4.1%N/A-43.8%$24.50MN/A0.003High Trading VolumeBTAIBioXcel Therapeutics4.5818 of 5 stars$6.40+58.4%$49.25+669.5%-52.3%$24.47M$2.27M-0.4790Short Interest ↓High Trading VolumeFBLGFibroBiologics2.7271 of 5 stars$0.55-4.8%$13.00+2,243.6%-58.3%$24.40MN/A0.0010Short Interest ↑MIRAMIRA Pharmaceuticals3.0364 of 5 stars$1.42+2.9%$17.00+1,097.2%-23.5%$23.35MN/A0.002Analyst UpgradeNAIINatural Alternatives InternationalN/A$3.70-0.1%N/A-28.5%$22.89M$113.80M-2.66290Gap DownHigh Trading VolumeCVKDCadrenal Therapeutics3.0578 of 5 stars$10.94-1.9%$32.00+192.5%+82.2%$22.82MN/A0.004 Related Companies and Tools Related Companies Biodexa Pharmaceuticals Alternatives Rein Therapeutics Alternatives NanoViricides Alternatives Tenax Therapeutics Alternatives JATT Acquisition Alternatives BioXcel Therapeutics Alternatives FibroBiologics Alternatives MIRA Pharmaceuticals Alternatives Natural Alternatives International Alternatives Cadrenal Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MYNZ) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mainz Biomed NV Please log in to your account or sign up in order to add this asset to your watchlist. Share Mainz Biomed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access